BeiGene, Ltd. - American Depositary Shares (ONC)

Competitors to BeiGene, Ltd. - American Depositary Shares (ONC)

Amgen, Inc. 

Amgen, Inc. competes with BeiGene in the oncology market, particularly in the development of biologic therapies. Both companies are focused on innovative therapeutics to treat cancer, but Amgen has the advantage of an established portfolio of FDA-approved products and a strong market presence. This gives Amgen a competitive edge in terms of revenue generation and resources available for research and development.

Blueprint Medicines Corporation 

Blueprint Medicines Corporation and BeiGene are both active in targeted cancer therapies, with Blueprint being renowned for its approach to genetic drivers of disease. While both companies develop drugs aimed at precision medicine, Blueprint has made significant progress in the approval of its therapies, giving it a competitive advantage in terms of market credibility and investor confidence. BeiGene's extensive pipeline offers broader options but lacks the market validation that Blueprint has achieved with its products.

Gilead Sciences, Inc. 

Gilead Sciences, Inc. competes with BeiGene by focusing on its oncology pipeline, which includes treatments for various cancers. Gilead has a strong reputation in antiviral therapies but is expanding into oncology. Their larger scale and financial capabilities provide them with an advantage in research funding and market access compared to BeiGene, which is still growing its presence in the oncology segment.

Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. competes with BeiGene in the realm of precision oncology, emphasizing targeted therapies for specific genetic mutations in tumors. Both companies have a strong focus on molecularly targeted therapies; however, Mirati has gained attention through its innovative compounds and partnerships, which provide it a competitive edge by facilitating quicker market entry and patient access compared to BeiGene's broader focus.

Regeneron Pharmaceuticals, Inc. 

Regeneron Pharmaceuticals, Inc. and BeiGene both invest heavily in novel treatments for cancer. While BeiGene focuses primarily on targeted therapies in its oncology portfolio, Regeneron also has a strong pipeline in immuno-oncology and a successful marketed product, Keytruda, giving it a competitive advantage in the market. Regeneron's established scientific expertise and commercialization strategy allow them a stronger foothold in the biotech arena.